Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PhD9 antibody
- Development stage
- Unknown
- Lead developer
- AntoXa
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (anticipated Based On Standard mAb Administration)
01
Overview
PhD9 antibody is a plant-made monoclonal antibody developed as a medical countermeasure for ricin exposure. It was originally developed by Defence Research & Development Canada (DRDC) and is being advanced by AntoXa Corporation under exclusive license from DRDC. The primary mechanism of action is the prevention of ricin toxin from penetrating cells, thereby neutralizing its toxic effects. Ricin is an extremely potent toxin derived from the castor bean plant (*Ricinus communis*) and classified as a Category B bioterrorism threat due to its lethality and ease of production. There are currently no approved antidotes for ricin poisoning; PhD9 represents a novel therapeutic approach with demonstrated efficacy in preclinical in vitro and in vivo studies. The drug candidate is produced using a proprietary plant-based manufacturing platform (vivoXPRESS®), which enables cost-effective large-scale production suitable for rapid deployment during biological emergencies[1][2][3][4][5][7].
- Other names
- anti-ricin monoclonal antibodyplant-made anti-ricin antibody
Beyond the preview
Go deeper on PhD9 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PhD9 antibody.